Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis

BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). The present study evaluated the impact of OCA therapy on lipoprotein sub-particles. METHOD: The study included...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hepatol
Main Authors: Siddiqui, Mohammad Shadab, Van Natta, Mark L., Connelly, Margery A., Vuppalanchi, Raj, Neuschwander-Tetri, Brent A., Tonascia, James, Guy, Cynthia, Loomba, Rohit, Dasarathy, Srinivasan, Wattacheril, Julia, Chalasani, Naga, Sanyal, Arun J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6920569/
https://ncbi.nlm.nih.gov/pubmed/31634532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2019.10.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados